The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

New research says the U.S. Census and Centers for Disease Control and Prevention have been miscounting Native American and ...

Between 2016 and 2023, the mental health of mothers in the U.S. significantly declined, according to new research. And while ...

The surgery was very difficult due to the size of the tumor and its attachment to the intestines, bladder and other organs. It was not easy to remove the tumor because it could accidentally damage any ...

Individuals with interstitial lung disease face a significantly higher risk of developing lung cancer than those without the ...

Topline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ...

The National Natural Science Foundation Project of China (No. 82271078) Youth Beijing Scholar (No.076) Beijing Municipal ...

This blood sugar feedback is considered extremely valuable for the optimal management of diabetes. It seems logical that the ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

PDF for Chemistry from the official Rajasthan Board website. Access chapter-wise details for Chemistry with the link to ...

From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions continue to assist pulmonologists.